Effect of Prior Transurethral Prostate Resection (TURP) or Laser Enucleation (ThuLEP) on Radiotherapy-Induced Toxicity and Quality of Life in Prostate Cancer Patients Undergoing Definitive Radiotherapy
by
, ,
David Rene Steike
1,*,
Fabian Martin Troschel
1,
Julian Roers
1,
Jan Jakob Siats
1,
Christopher Kittel
1,
Niklas Benedikt Pepper
1,
Stefan Gravemeyer
1,
Philipp Papavassilis
2,
Andres Jan Schrader
2,
Hans Theodor Eich
1 and 
Sergiu Scobioala
1 1
Department of Radiooncology, University Hospital Muenster, 48149 Muenster, Germany
2
Department of Urology, University Hospital Muenster, 48149 Muenster, Germany
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(19), 3403; https://doi.org/10.3390/cancers16193403
Submission received: 28 August 2024
/
Revised: 1 October 2024
/
Accepted: 3 October 2024
/
Published: 6 October 2024
(This article belongs to the Special Issue New Insights into Prostate Cancer Radiotherapy)
Simple Summary
In the radio-oncological treatment of patients with prostate cancer, there are significant differences in therapy tolerance due to risk factors, previous illnesses, and pre-treatment of the prostate. Patients with previous prostate surgery (TURP or ThuLEP) are a significant risk group in prostate cancer treatment and differ from non-operated patients in terms of quality of life. Patients who underwent transurethral prostate resection (TURP) exhibited greater overall quality of life impairment immediately after radiotherapy compared to those who had transurethral laser enucleation (ThuLEP) or no surgery. Operation time and radiation technique are important factors regarding therapy tolerance.
Abstract
In our study, the post-radiotherapy quality of life of prostate cancer patients who previously underwent transurethral resection of the prostate (TURP) is compared to those who had thulium laser enucleation of the prostate (ThuLEP) and those who had no prior surgery. It also aims to identify and assess risk factors affecting therapy tolerance in this patient group. We analyzed 132 patients with localized prostate cancer treated with definitive radiotherapy (RT), including 23 who had prior TURP and 19 who previously underwent ThuLEP. A total of 62% of patients underwent irradiation within 12 months after surgery. We included only patients treated with radiotherapy using the IMRT technique. Changes in patient-reported urinary toxicity were evaluated using the International Prostate Syndrome Score (IPSS) and the quality of life index of the World Health Organization (QoL/WHO-PSS) over a three-year post-radiotherapy period. Patients with prior TURP experienced significant deterioration in QoL and IPSS immediately after irradiation (p < 0.001), whereas those without previous surgery showed both less significant differences in IPSS and QoL scores. In conclusion, patients with previous TURP/ThuLEP differ from those without previous surgery in urinary quality of life and acute and chronic urinary symptom profiles after RT. The surgical technique (ThuLEP vs. TURP) and the time interval to irradiation are crucial factors affecting RT tolerance in acute and late settings. The previously operated patient group reported a significantly longer period of increased symptom burden.
